Current status and new developments in Peyronie's disease: Medical, minimally invasive and surgical treatment options

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 6, 2011, Pages 931-944

  Gur, Serap ^a   Limin, Ma ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

collagenase; incision and grafting; interferon; Peyronie's disease; tunical lengthening procedures

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CARNITINE; COLCHICINE; COLLAGENASE; CORTICOSTEROID; LIDOCAINE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TAMOXIFEN; UNCLASSIFIED DRUG; VERAPAMIL; XIAFLEX;

BURN; CALCIFICATION; DRUG INDUCED HEADACHE; DUPUYTREN CONTRACTURE; EXTRACORPOREAL LITHOTRIPSY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IMPOTENCE; INFLAMMATION; IONTOPHORESIS; LIBIDO DISORDER; MINIMALLY INVASIVE SURGERY; NAUSEA; NONHUMAN; PENILE FIBROSIS; PENIS PROSTHESIS; PEYRONIE DISEASE; REVIEW; SKIN ULCER; SURGICAL TECHNIQUE; TRACTION THERAPY; TUNICA ALBUGINEA; VOMITING;

4-AMINOBENZOIC ACID; COLCHICINE; COLLAGENASES; DRUG ADMINISTRATION ROUTES; HUMANS; INTERFERON-ALPHA; MALE; PENILE IMPLANTATION; PENILE INDURATION; PENIS; PHARMACEUTICAL PREPARATIONS; PUBMED; RADIOTHERAPY; SURGICAL PROCEDURES, MINIMALLY INVASIVE; VERAPAMIL; VITAMIN E;

EID: 79952741381     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.544252     Document Type: Review

References (115)

1. Dunsmuir WD, Kirby RS. Francois de LaPeyronie (1978-1747): the man and the disease he described. Br J Urol 1996;78:613-22 (Pubitemid 127798034)
2. Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie's disease. Drugs 2007;67:527-45 (Pubitemid 46440311)
3. Hellstrom WJ. Medical management of Peyronie's disease. J Androl 2009;30:397-405
4. Muller A, Mulhall JP. Peyronie's disease intervention trials: methodological challenges and issues. J Sex Med 2009;6:848-61
5. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9
6. Gholami SS, Gonzalez-Cadavid NF, Lin CS, et al. Peyronie's disease: a review. J Urol 2003;169:1234-41 (Pubitemid 36323758)
7. Bella AJ, Perelman MA, Brant WO. Lue TF. Peyronie's disease (CME). J Sex Med 2007;4:1527-38
8. Lin CS, Lin G, Wang Z, et al. Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Biochem Biophys Res Commun 2002;295:1014-19
9. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005;2:291-7 (Pubitemid 40903186)
10. Fornara P, Gerbershagen HP. Ultrasound in patients affected with Peyronie's disease. World J Urol 2004;22:365-7 (Pubitemid 40227549)
11. Bekos A, Arvaniti M, Hatzimouratidis K, et al. The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol 2008;53:644-50
12. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997;157:311-15 (Pubitemid 26414981)
13. Greenfield JM, Levine LA. Peyronie's disease: etiology, epidemiology and medical treatment. Urol Clin North Am 2005;32:469-78 (Pubitemid 41607533)
14. Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948;41:173-7
15. Scardino PL, Kelley RA, Scott WW. Seminal tract tuberculosis: an evaluation of Young's radical operation for eradication of tuberculosis of the prostate, seminal vesicles, vasa and epididymides. J Urol 1950;63:698-711
16. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007;178:1398-403 (Pubitemid 47368421)
17. Hashimoto K, Hisasue S, Kato R, et al. Outcome analysis for conservative management of Peyronie's disease. Int J Urol 2006;13:244-7
18. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-6
19. Pryor J, Akkus E, Alter G, et al. Peyronie's disease. J Sex Med 2004;1:110-15 (Pubitemid 40424674)
20. Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5
21. Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994;44:291-5 (Pubitemid 24246173)
22. Lin G, Shindel AW, Banie L, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010;7:1787-97
23. Valente EG, Vernet D, Ferrini MG, et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003;9:229-44 (Pubitemid 38294362)
24. Takami M, Cho ES, Lee SY, et al. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 2005;579:832-8
25. Ferrini MG, Kovanecz I, Nolazco G, et al. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006;97:625-33
26. Vernet D, Ferrini MG, Valente EG, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002;7:262-76 (Pubitemid 35365671)
27. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994;151:1522-4 (Pubitemid 24151291)
28. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002;168:621-6
29. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002;168:2483-5 (Pubitemid 35402645)
30. Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C [Iontophoresis in the conservative treatment of Peyronie's disease: preliminary experience]. Arch Ital Urol Androl 1997;69:323-7
31. Cabello Benavente R, Moncada Iribarren I, de Palacio Espana A, et al. Transdermal iontophoresis with dexamethasone and verapamil for Peyronie's disease. Actas Urol Esp 2005;29:955-60 (Pubitemid 44964592)
32. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003;169:1775-8 (Pubitemid 36443494)
33. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006;49:987-97 (Pubitemid 43673989)
34. Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004;171:1605-8 (Pubitemid 38365431)
35. Hellstrom WJ, Cockerham YR. Intralesional injection therapy for Peyronie's disease. J Sex Med 2009;6:1811-14
36. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007;69:1181-4 (Pubitemid 46891587)
37. Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol 2007;51:640-7 (Pubitemid 46097281)
38. Roth M, Eickelberg O, Kohler E, et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996;93:5478-82
39. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002;14:397-405 (Pubitemid 35285291)
40. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998;51:620-6 (Pubitemid 28186217)
41. Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology 1983;21:584-5 (Pubitemid 13078860)
42. Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23 (Pubitemid 40424662)
43. Kendirci M, Usta MF, Matern RV, et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005;2:709-15 (Pubitemid 41742931)
44. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997;79:40-2 (Pubitemid 28318842)
45. Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997;32:190-3 (Pubitemid 27386960)
46. Duncan MR, Hasan A, Berman B. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol 1995;104:282-6
47. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha,-beta and-gamma. Scand J Urol Nephrol 1991;25:89-94
48. Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8 (Pubitemid 43833173)
49. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009;361:968-79
50. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982;10:135-40 (Pubitemid 12046996)
51. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993;149:56-8 (Pubitemid 23095473)
52. Jordan GH. The use ofintralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008;5:180-7
53. Ehrlich HP. Scar contracture: cellular and connective tissue aspects in Peyronie's disease. J Urol 1997;157:316-19 (Pubitemid 26414982)
54. Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009;56:363-9
55. Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie's disease. Urology 2002;60:795-800
56. Hauck EW, Mueller UO, Bschleipfer T, et al. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol 2004;171:740-5 (Pubitemid 38090471)
57. Furlow WL, Swenson HE Jr, Lee RE. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975;114:69-71
58. Mulhall JP, Branch J, Lubrano T, Shankey TV. Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. J Urol 2003;170:281-4 (Pubitemid 36734479)
59. Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009;6:558-66
60. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med 2008;5:1468-73 (Pubitemid 351803113)
61. Kadioglu A, Sanli O, Akman T, et al. Surgical treatment of Peyronie's disease: a single center experience with 145 patients. Eur Urol 2008;53:432-9
62. Kayigil O, Agras K, Aldemir M, Okulu E. The combination of vein grafting and two different types of corporeal plication in complex curvature due to Peyronie's disease. Urol Int 2010;84:275-81
63. Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 1965;93:230-2
64. Chand N, Eyre P. Classification and biological distribution of histamine receptor sub-types. Agents Actions 1975;5:277-95
65. Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie's disease. J Urol 1979;122:622-3 (Pubitemid 10163229)
66. Dugi DD III, Morey AF. Penoscrotal plication as a uniform approach to reconstruction of penile curvature. BJU Int 2010;105:1440-4
67. Bokarica P, Parazajder J, Mazuran B, Gilja I. Surgical treatment of Peyronie's disease based on penile length and degree of curvature. Int J Impot Res 2005;17:170-4 (Pubitemid 40434592)
68. Rolle L, Tamagnone A, Timpano M, et al. The Nesbit operation for penile curvature: an easy and effective technical modification. J Urol 2005;173:171-4
69. Bella AJ, Beasley KA, Obied A, Brock GB. Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. Urology 2006;68:852-7 (Pubitemid 44633383)
70. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol 2006;175:238-41 (Pubitemid 41797159)
71. Moyano Calvo JL, Sanchez de la Vega J, Giraldez Puig J, et al. Our experience with the Nesbit technique for the treatment of Peyronie's disease. Arch Esp Urol 2006;59:511-15 (Pubitemid 44084910)
72. Paez A, Mejias J, Vallejo J, et al. Long-term patient satisfaction after surgical correction of penile curvature via tunical plication. Int Braz J Urol 2007;33:502-9
73. Taylor FL, Levine LA. Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med 2008;5:2221-30
74. Ding S, Lu J, Zhang H, et al. A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease. Int Urol Nephrol 2010;42(3):597-602
75. Tornehl CK, Carson CC. Surgical alternatives for treating Peyronie's disease. BJU Int 2004;94:774-83 (Pubitemid 39472468)
76. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 2002;167:2066-9 (Pubitemid 34309662)
77. Simonato A, Gregori A, Varca V, et al. Penile dermal flap in patients with Peyronie's disease: long-term results. J Urol 2010;183:1065-8
78. Cormio L, Zucchi A, Lorusso F, et al. Surgical treatment of Peyronie's disease by plaque incision and grafting with buccal mucosa. Eur Urol 2009;55:1469-75
79. Radopoulos D, Vakalopoulos I, Thanos P. Preputial graft in penile curvature correction: preliminary results. Int J Impot Res 2009;21:82-7
80. Liu B, Zhu XW, Zhong DC, et al. Replacement of plaque by buccal mucosa in the treatment of Peyronies disease: a report of 27 cases. Zhonghua Nan Ke Xue 2009;15:45-7
81. Goyal NK, Kumar A, Das SK, et al. Experience with plaque excision and dermal grafting in the surgical treatment of Peyronie's disease. Singapore Med J 2008;49:805-8
82. Breyer BN, Brant WO, Garcia MM, et al. Complications of porcine small intestine submucosa graft for Peyronie's disease. J Urol 2007;177:589-91 (Pubitemid 46054020)
83. Hsu GL, Chen HS, Hsieh CH, et al. Long-term results of autologous venous grafts for penile morphological reconstruction. J Androl 2007;28:186-93
84. Knoll LD. Use of porcine small intestinal submucosal graft in the surgical management of tunical deficiencies with penile prosthetic surgery. Urology 2002;59:758-61 (Pubitemid 34461991)
85. Knoll LD. Re: porcine small intestinal submucosa is not an ideal graft material for Peyronie's disease surgery. John T, Bandi G Santucci R, editors. J Urol 2006;176:1025-1029
86. J Urol 2007;177:1204
87. Craatz S, Spanel-Borowski K, Begemann JF, et al. The dorsal lamina of the rectus sheath: a suitable grafting material for the penile tunica albuginea in Peyronie's disease? BJU Int 2006;97:134-7
88. Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie's disease. BJU Int 2005;95:1029-33 (Pubitemid 40655699)
89. Shioshvili TJ, Kakonashvili AP. The surgical treatment of Peyronie's disease: replacement of plaque by free autograft of buccal mucosa. Eur Urol 2005;48:129-5
90. Lahme S, Gotz T, Bichler KH. Collagen fleece for defect coverage following plaque excision in patients with Peyronie's disease. Eur Urol 2002;41:401-5 (Pubitemid 35333936)
91. Kadioglu A, Sanli O, Akman T, et al. Graft materials in Peyronie's disease surgery: a comprehensive review. J Sex Med 2007;4:581-95 (Pubitemid 46779294)
92. Ma LM, Jiang H, Zhou J, et al. Snodgrass technique, Duckett repair and bladder mucosa grafting for hypospadias: an analysis of 251 cases. Zhonghua Nan Ke Xue 2009;15:1068-71
93. Dublin N, Stewart LH. Oral complications after buccal mucosal graft harvest for urethroplasty. BJU Int 2004;94:867-9 (Pubitemid 39472486)
94. Santucci RA, Barber TD. Resorbable extracellular matrix grafts in urologic reconstruction. Int Braz J Urol 2005;31:192-203 (Pubitemid 41030421)
95. Sievert KD, Tanagho EA. Organ-specific acellular matrix for reconstruction of the urinary tract. World J Urol 2000;18:19-25
96. John T, Bandi G, Santucci R. Porcine small intestinal submucosa is not an ideal graft material for Peyronie's disease surgery. J Urol 2006;176:1025-9 (Pubitemid 44142609)
97. Fu Q, Cao YL. Use of tissue engineering in treatment of the male genitourinary tract abnormalities. J Sex Med 2010;7:1741-6
98. Chaudhary M, Sheikh N, Asterling S, et al. Peyronie's disease with erectile dysfunction: penile modeling over inflatable penile prostheses. Urology 2005;65:760-4 (Pubitemid 40523014)
99. Henry GD, Wilson SK. Updates in inflatable penile prostheses. Urol Clin NorthAm 2007;34:535-47 (Pubitemid 350029955)
100. Taylor FL, Levine LA. Peyronie's disease. Urol Clin North Am 2007;34:517-34 (Pubitemid 350029957)
101. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010;7:2359-74
102. Smith JF, Walsh TJ, Lue TF. Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res 2008;20:445-59
103. Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9 (Pubitemid 47079641)
104. Grasso M, Lania C, Fortuna F, et al. Preservation of cavernosal erectile function after soft penile prosthesis implant in Peyronie's disease: long-term followup [Article id: 646052]. Adv Urol 2008. [Epub 2 December 2008]
105. Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002;14:406-10 (Pubitemid 35285292)
106. El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997;158:1391-4
107. Haag SM, Hauck EW, Szardening-Kirchner C, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007;51:255-61 (Pubitemid 44821507)
108. Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001;165:419-23 (Pubitemid 32060427)
109. Vernet D, Nolazco G, Cantini L, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod 2005;73:1199-210 (Pubitemid 41698610)
110. Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J Sex Med 2009;6:1729-35
111. Agrawal V, Ellins E, Donald A, et al. Systemic vascular endothelial dysfunction in Peyronie's disease. J Sex Med 2008;5:2688-93
112. Ryu JK, Piao S, Shin HY, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009;6:1284-96
113. Ding S, Lu J, Zhang H, et al. A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease. Int Urol Nephrol 2010;42(3):597-602
114. Austoni E, Colombo F, Romano AL, et al. Soft prosthesis implant and relaxing albugineal incision with saphenous grafting for surgical therapy of Peyronie's disease: a 5-year experience and long-term follow-up on 145 operated patients. Eur Urol 2005;47(2):223-9; discussion 229. (PMID: 15661418) (Pubitemid 40126982)
115. Knoll LD. Use ofsmall intestinal submucosa graft for the surgical management of Peyronie's disease. J Urol 2007;178:2474-8; discussion 2478 (Pubitemid 350052188)